ASCO: First-Line Sunvozertinib Beats Chemo for Advanced NSCLC

THURSDAY, June 4, 2026-- For patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, sunvozertinib is superior to chemotherapy for first-line treatment, according to a...